Gene fusions resulting from rearrangements of Janus kinase 2 (JAK2) or erythropoietin receptor (EPOR) are associated with inferior outcomes in Ph-like ALL patients13. This evidence concerns the gene EPOR and acute lymphoblastic leukemia.